Drug Profile
Research programme: chikungunya virus vaccines - Takeda/University of Texas Medical Branch
Alternative Names: Recombinant CHIKV/IRES vaccine - Takeda/UTMBLatest Information Update: 24 Jul 2014
Price :
$50
*
At a glance
- Originator University of Texas Medical Branch
- Developer Takeda Pharmaceuticals USA; University of Texas Medical Branch
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chikungunya virus infections
Most Recent Events
- 24 Jul 2014 No development reported - Preclinical for Chikungunya virus infections in USA (Parenteral)
- 31 May 2013 Inviragen has been acquired by Takeda Pharmaceuticals USA